$XBI $159.07 +2% đ
Want to access our searchable database of catalysts and more? Get access to BiopharmIQ for 30 days free, no credit card required. Check it out here!
Pipeline Updates
$DTIL +8% 3-year pre-clinical data in non-human primates shows durability and safety of ARCUS gene-editing to cut LDL cholesterol level. source
$IMCR +3% Tebentafusp granded Breakthrough Therapy Designation by FDA for unresectable or metastatic uveal melanoma. source
$INSM +1% Topline results from phase 1 study of Treprostinil Palmitil Inhalation Powder (TPIP). source
$DVAX +6% MAA approval for HEPLISAV B an adult Hepatitis B adjuvanted vaccine. source
$EOLS +72% Litigation settlement agreements to fully resolve all outstanding litigation, including the United States International Trade Commission (ITC) case regarding the sale of JeuveauÂŽ, between the companies. A California court case filed by Medytox against Evolus will be dismissed. source
Financial Updates
$AYLA +16% $25M private offering. source